The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Febuxostat
Febuxostat · FEBUXOSTAT 40 mg/1 · Tablet, Film Coated · Oral · Sun Pharmaceutical Industries, Inc.
NDC 47335-0721-13 · 500 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 72205-0028-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.9092per unit
middle half $0.4900–$2.55 · 4,463 plans · Jan 1, 2026
Est. net of rebatesⓘ
≈ $0.9092
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
81%of plans cover it
tier 3 · prior auth 7% · step therapy 67% · qty limit 30%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 9 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for febuxostat (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA205467
- TE code
- AB
- Approval date
- Jul 1, 2019
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · CompletedJan 18, 2024SUN PHARMACEUTICAL INDUSTRIES INC — CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
- Class II · CompletedJan 18, 2024SUN PHARMACEUTICAL INDUSTRIES INC — CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
Manufacturers of Febuxostat (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| American Health Packaging | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NorthStar RxLLC | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NorthStar RxLLC | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals, Inc. | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | FEBUXOSTAT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | FEBUXOSTAT 40 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Febuxostat — NDC 47335-0721-13," retrieved September 3, 2026, https://drugdashboards.com/drug/47335072113.
Free to cite with attribution — see how the data is put together.